KenOliveLab

OK, this one is really meaningful for our whole team. Our preclinical paper on pan-RAS inhibition in pancreatic cancer is now online @Nature. Led by OliveLab student @ulawasko and Revolution Medicines colleagues JingJing Jiang and Mallika Singh. nature.com/articles/s4158…

@NCICancerBio @ednacukierman @DelgiornoKathy @CJHPhD @AshleyKiemen @Aiims1742 @CancerHacker @MaraShermanLab @NinaSteele17 Thanks for the invitation to participate! To all those who are reading, most of my social media activity going forward is on the site with the butterfly (same handle). Hope to see you over there!

@NCICancerBio A9: There is an explosion of research in cancer-associated cachexia & this will be of hugely important to patients. #PDAC is the most pro-cachexia malignancy and this profoundly affects patient quality of life. Cancer therapy needs to add high quality life, not just extra time.

@CJHPhD @NCICancerBio Yeah, I think that basically every topic of research in the PDAC field will need to be revisited in the context of RAS inhibition. When it becomes part of the SOC, eventually nearly all PDAC tumors will have seen RAS inhibitor at some point in their treatment history.

@NCICancerBio A8: Regarding treatment, it will be interesting to see our focus in the new landscape of readily available KRAS inhibitors. Otherwise, we desperately need early detection methods that account for the fact that precursor lesions are more common than we realized. #PCAMChat24

@NCICancerBio A8: Physicians are seeing more and more young-onset #PancreaticCancer cases. We need to understand the etiology and go big on prevention and early interception strategies. #PCAMChat24

@NCICancerBio That is, specifically on spatial data.

@NCICancerBio A7: A major key here will be in the analysis tools used to explore these (absolutely massive) datasets. We are again in a situation where our ability to generate data is outstripping the tools we have to analyze. I'm excited by the potential for leveraging powerful sysbio tools!

@DelgiornoKathy @NCICancerBio @AshleyKiemen Yes. These tools have incredible potential power and need to be used more widely!

Artificial Intelligence is taking #PancreaticCancer research by storm! Algorithms that assess pathology, like CODA developed by @AshleyKiemen, are dissecting the physical changes associated with evolution of the epithelium from benign to malignant disease. AI applied to patient scans has the potential to more accurately stratify patients with cysts for resection vs. monitoring.

@NCICancerBio I was pretty sure that everyone else could type "spatial transcriptomics!" faster than I could. ;-)

@NCICancerBio Another big question will be the difference between mutation-selective RAS inhibitors and pan-RAS inhibitors. There are potential advantages and disadvantages to each strategy. Maybe the answer is both?

@NCICancerBio As @cemccarthy02 is highlighting, the next big question will be what to combine with RAS inhibitors. It is on the preclinical PDAC research community to figure this out. Immunotherapy, other targeted therapies, metabolic therapies, etc.

@NCICancerBio A6: Definitely need to highlight RAS inhibition as the dawn of a new era for the treatment of #PDAC patients. The remarkable progress of pan-RAS inhibitors in the clinic (now in Phase 3!) has be super excited and closely linked to preclinical development efforts. #PCAMChat24

Sad to miss the first #PCAMChat24. Briefly, this is Ken Olive from @columbiacancer. I lead a translational research lab dedicated to #PDAC research. Excited to join in for part 2!

@cemccarthy02 @NCICancerBio

@NCICancerBio A1: Hi everyone! I’m back for Part 2 to share my #scicomm perspective on #PancreaticCancer research. #PCAMChat24

Suddenly seeing a huge number of fellow scientists show up on BlueSky. FYI I'm one of them. Come follow me: @kenolivelab.bsky.social

ICYMI, the new issue of @CR_AACR is online and features the print version of the In Focus commentary #PancreaticCancer–Associated Fibroblasts: Where Do We Go from Here? aacrjournals.org/cancerres/arti… By Eileen Carpenter, @DebVendramini @MC_Hasselluhn @MaraShermanLab @Pasca_Lab @ednacukierman @KenOliveLab

New post on our website with updated information on the clinical development of RAS inhibitors for pancreatic cancer. I'll summarize on twitter sooner, but here's the full version: olivelab.org/ras-inhibitor-…

@Aiims1742 @PancPathologist @lauradelongwood @deniswirtz These drawings are spectacular. Extraordinary intersection of art and science!

The first known histological description of precursor lesions of #PancreaticCancer was ~120 years ago (in 1905 to be precise). In this paper, the hand drawn illustrations by Dr. Hulst bear a striking resemblance to lesions that we would today call "pancreatic intraepithelial neoplasia" or PanINs. Thanks to @RalphHruban for teaching me the history of the pancreas (along with pancreatic pathology!) link.springer.com/article/10.100…

On behalf of our Phase I program @columbiacancer , proud of @bherzbergmd presenting exciting initial data on IDE397 in MTAP-del tumors at the @EORTC - @theNCI - @AACR conference ir.ideayabio.com/2024-10-25-IDE… We are excited to offer this study to our patients recruit.cumc.columbia.edu/studyinfopage/…

@AlvaroCurielGa1 @NIH It's cool, but is it me or is @nih sending some subtle hints about the relative importance of immune cells vs. fibroblasts here...

A cool and FREE tool for #Scientists @NIH just created a library of thousands of scientific illustrations that can help in making FIGURES, PPT,... The name: BIOART Here the link: bioart.niaid.nih.gov

@Phillips1Phoebe @PanKind_APCF Thanks so much! @ulawasko is a superstar! Really appreciate @PanKind_APCF for hosting her visit!!

@KenOliveLab it was wonderful seeing your teams impressive results with Kras inhibitor presented by the very talented Ula Wasko at our @PanKind_APCF meeting yesterday. Congratulations! thank you Ula for all your contributions on panels at our meeting. I hope you are well Ken!